The non-responder gap matters for two reasons: First, patients who are in an advanced stage of cancer lose valuable time in ineffective therapy. Second, it increases the cost of therapy and resources for both patients and the broader healthcare ecosystem.
The post An AI Driven Approach to Address the Non-Responder Gap in Radiopharmaceutical Therapy appeared first on MedCity News.
